Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Non-Current Assets: 2022-2024

Historic Non-Current Assets for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $86.3 million.

  • Entrada Therapeutics' Non-Current Assets fell 16.37% to $74.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.6 million, marking a year-over-year decrease of 16.37%. This contributed to the annual value of $86.3 million for FY2024, which is 13.22% down from last year.
  • Per Entrada Therapeutics' latest filing, its Non-Current Assets stood at $86.3 million for FY2024, which was down 13.22% from $99.4 million recorded in FY2023.
  • Entrada Therapeutics' Non-Current Assets' 5-year high stood at $99.4 million during FY2023, with a 5-year trough of $42.2 million in FY2022.
  • In the last 3 years, Entrada Therapeutics' Non-Current Assets had a median value of $86.3 million in 2024 and averaged $76.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 135.70% in 2023, then dropped by 13.22% in 2024.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Non-Current Assets stood at $42.2 million in 2022, then soared by 135.70% to $99.4 million in 2023, then decreased by 13.22% to $86.3 million in 2024.